Poehling Capital Management INC. Sells 101,256 Shares of Organon & Co. $OGN

Key Points

• Poehling Capital Management cut its Organon stake by 31.9% in the fourth quarter, selling 101,256 shares and leaving it with 216,492 shares worth about $1.55 million.
• Organon’s latest results came in below expectations, with quarterly EPS of $0.71 versus $0.83 expected and revenue of $1.46 billion versus $1.49 billion forecast.
• Mixed signals from investors and analysts: an Organon executive recently bought shares, while analysts currently have a consensus “Reduce” rating and a $11.40 price target.

Poehling Capital Management INC. lessened its position in Organon & Co. (NYSE:OGN - Free Report) by 31.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 216,492 shares of the company's stock after selling 101,256 shares during the quarter. Poehling Capital Management INC. owned 0.08% of Organon & Co. worth $1,552,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in OGN. Vanguard Group Inc. grew its stake in shares of Organon & Co. by 11.3% during the third quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company's stock valued at $383,715,000 after buying an additional 3,650,860 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Organon & Co. by 136.1% during the second quarter. AQR Capital Management LLC now owns 3,254,884 shares of the company's stock valued at $31,507,000 after buying an additional 1,876,264 shares during the last quarter. UBS Group AG grew its stake in shares of Organon & Co. by 55.2% during the fourth quarter. UBS Group AG now owns 4,295,002 shares of the company's stock valued at $30,795,000 after buying an additional 1,527,492 shares during the last quarter. Balyasny Asset Management L.P. grew its stake in shares of Organon & Co. by 102.1% during the third quarter. Balyasny Asset Management L.P. now owns 2,240,149 shares of the company's stock valued at $23,925,000 after buying an additional 1,131,941 shares during the last quarter. Finally, Gotham Asset Management LLC grew its stake in shares of Organon & Co. by 37.2% during the third quarter. Gotham Asset Management LLC now owns 3,713,204 shares of the company's stock valued at $39,657,000 after buying an additional 1,007,691 shares during the last quarter. Institutional investors own 77.43% of the company's stock.

Organon & Co. Stock Performance

Organon & Co. stock opened at $13.44 on Wednesday. The company has a current ratio of 1.97, a quick ratio of 1.42 and a debt-to-equity ratio of 9.47. The firm has a 50-day moving average of $9.02 and a 200-day moving average of $8.11. The firm has a market cap of $3.53 billion, a P/E ratio of 14.45, a P/E/G ratio of 1.24 and a beta of 1.57. Organon & Co. has a 1-year low of $5.69 and a 1-year high of $13.47.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported $0.71 earnings per share for the quarter, missing analysts' consensus estimates of $0.83 by ($0.12). The firm had revenue of $1.46 billion for the quarter, compared to analysts' expectations of $1.49 billion. Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.The business's revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.02 earnings per share. Sell-side analysts expect that Organon & Co. will post 3.23 EPS for the current year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 11th. Stockholders of record on Monday, May 11th will be issued a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Monday, May 11th. Organon & Co.'s dividend payout ratio is currently 8.60%.

Insider Buying and Selling at Organon & Co.

In other news, SVP Lynette Holzbaur bought 26,448 shares of the company's stock in a transaction dated Wednesday, May 6th. The stock was bought at an average cost of $13.35 per share, for a total transaction of $353,080.80. Following the completion of the acquisition, the senior vice president owned 52,851 shares in the company, valued at approximately $705,560.85. This trade represents a 100.17% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.62% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on OGN. Piper Sandler raised Organon & Co. from an "underweight" rating to a "neutral" rating and raised their price objective for the company from $5.00 to $14.00 in a research note on Tuesday, April 28th. Wall Street Zen cut Organon & Co. from a "buy" rating to a "hold" rating in a research note on Saturday, January 31st. BNP Paribas Exane reaffirmed a "neutral" rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Zacks Research raised Organon & Co. from a "strong sell" rating to a "hold" rating in a research note on Tuesday, April 14th. Finally, Barclays raised their price objective on Organon & Co. from $7.50 to $8.00 and gave the company an "underweight" rating in a research note on Tuesday, February 24th. Five investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Reduce" and a consensus price target of $11.40.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.